Drug Trial Radar · NCT03660800
Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Aug 20, 2018
Primary completion
Oct 24, 2018
Study completion Jan 22, 2019
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and non-Japanese Healthy Subjects
Conditions
- Vitamin D Insufficiency
- Secondary Hyperparathyroidism
Interventions
CTAP101 CapsulesDrug
Calcifediol Extended-Release Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related AEs as assessed by industry standardsTime frame: 8 weeks
- Change in baseline of peak plasma concentrationTime frame: 8 weeks
- Change in mean total of the different components of calcifediolTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WCCT Global, Inc.
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.